Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of subcutaneous nipocalimab in healthy volunteers
NL-OMON50999Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, double-blind trial of nipocalimab in autoimmune disease and Inflammatory Disorders (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Safety and tolerability. Started May 2021; status: completed.
02
Drugs
nipocalimab
03
Conditions
autoimmune diseaseInflammatory Disorders
Beyond the preview
Go deeper on NL-OMON50999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50999.